Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Drug Class Analysis GLP-1 Weight Loss Drug Market by Drug Class: Injectable and Dual Agonist Therapies Command 78.4% of Revenue Drug Class Revenue Share, CAGR, and Commercial Drivers GLP-1 Obesity Drug Market 2026 Injectable GLP-1 receptor agonist monoagonists hold a 32.8% GLP-1 market revenue share in 2026 , reflecting Wegovys position as the most commercially successful weight management drug in pharmaceutical history
European Journal of Nutrition
Read on for a closer look at the science behind these drugs and the different opinions surrounding their increasingly popular role in weight loss
[7] The drug remains in clinical development, with Phase 3 trials ongoing under Eli Lilly's research programme
US$ 29.77
US$ 28.71
US$ 21.12
US$ 20.98
